A major obstacle in treating neurological diseases and brain tumors is to deliver drugs or antibodies across the ‘blood brain barrier’ (BBB). My lab’s recent discoveries have changed our understanding of how the BBB restricts blood-brain communication. The BBB is formed by a single layer of endothelial cells that lines the blood vessel walls and act as a gatekeeper for the brain. Historically, the restricted permeability of brain vasculature has been attributed to tight junctions. However, substances can also cross endothelial cells by transcytosis, and we discovered that transcytosis is actively inhibited in brain endothelial cells. We identified a novel multi-transmembrane protein Mfsd2a as a key regulator for BBB function, and demonstrated that interfering with Mfsd2a and its downstream pathway upregulates transcytosis and causes the BBB to become permeable. We propose to develop therapeutic agents that specifically target Mfsd2a function as a strategy to facilitate drug delivery across the BBB.

Funding

Funding Duration

July 1, 2019 - June 30, 2021

Funding level

Development

People

Principal Investigator

Chenghua Gu

PhD
Professor of Neurobiology, Harvard Medical School
Co-PI

Urs Langen

PhD
Research Fellow in Neurobiology (INT), Harvard Medical School

Intellectual Property

Publications

Patents

HU 4703
:
Methods and compositions relating to modulation of the permeability of the blood brain barrier
(Abandoned)
WO2022155410
:
Structure and mechanisms of the blood-brain barrier DHA transporter Mfsd2a
(Patent application)